Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02061306 · ClinicalTrials.gov registry record
Celiac Disease Genomic Environmental Microbiome and Metabolomic Study
A clinical trial of Celiac Disease, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- 500
- Enrollment target
- 2
- Study locations
NCT02061306 is a study of Celiac Disease that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 500 participants, below the 1,959-participant average among 24 other Celiac Disease trials with a reported enrollment target (74% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT02061306, a study of Celiac Disease, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 2
- Study locations
Study Summary
Celiac disease (CD) is a complex disease caused by eating gluten, a protein contained in wheat, rye, and barley. It is well known that many factors contribute to the development of CD, including the genes that you have and the foods that you eat. In the CDGEMM study, we will consider as many of these factors as possible and study how they each contribute to disease development. If the investigators find that any one factor, or combination of factors, increases the risk of developing CD, we will be able to apply this information and help prevent or detect disease in high-risk children in the future.
Conditions Studied
Study Locations (2)
Massachusetts
- MassGeneral Hospital for Children - Boston
Other
- University of Roma La Sapienza - Rome
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2014-03 |
| Est. Completion | 2025-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02061306
The ClinicalTrials.gov registry entry for NCT02061306 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,959-participant average among 24 other Celiac Disease trials with a reported enrollment target (74% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Celiac Disease appearing as the primary indexed condition, and to 0 interventions.
NCT02061306 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Other.
Frequently Asked Questions
What is clinical trial NCT02061306 about?
NCT02061306 is a clinical study titled "Celiac Disease Genomic Environmental Microbiome and Metabolomic Study". Celiac disease (CD) is a complex disease caused by eating gluten, a protein contained in wheat, rye, and barley. It is well known that many factors contribute to the development of CD, including the genes that you have and the foods that you eat. In the CDGEMM study, we will consider as many of thes...
What is the current status of trial NCT02061306?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2014-03. Estimated completion is 2025-12.
What conditions does trial NCT02061306 study?
This clinical trial studies the following conditions: Celiac Disease.
Who is sponsoring clinical trial NCT02061306?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02061306 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Celiac Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tissue Destruction and Healing in Celiac Disease
RECRUITING · NA
-
A First-in-human Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease
RECRUITING · Phase 1
-
Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
RECRUITING
-
Immune Responses to Gluten
RECRUITING · NA
-
Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission
RECRUITING · Phase 2
-
Urine Metabolites in the Diagnosis of Disease
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.